A recent study confirmed the synergistic action of KRAS and tumor suppressor gene mutations for development of IPMN in animal model and highlighted the role of Wnt/β-catenin pathway in KRAS-associated lesions [73]. Here, KRAS is linked to pancreatic intraductal papillary-mucinous neoplasm.